Evidence map›Paper›PMID 37264897›Full record

ArticleClinical trials (London, England)2023

Now is the time to fix the clinical research workforce crisis.

Stephanie A Freel, Denise C Snyder, Kara Bastarache, Carolynn Thomas Jones, Mark B Marchant, Laura A Rowley, Stephen A Sonstein, Karen M Lipworth, Susan P Landis

Abstract read
In one paragraph

Article in Clinical trials (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Stephanie A FreelDuke Office of Clinical Research, Duke University School of Medicine and Duke Clinical Translational Science Institute, Duke University, Durham, NC, USA.ORCID 0000-0002-8525-3271
Denise C SnyderDuke Office of Clinical Research, Duke University School of Medicine and Duke Clinical Translational Science Institute, Duke University, Durham, NC, USA.
Kara BastaracheAssociation of Clinical Research Professionals, Alexandria, VA, USA.
Carolynn Thomas JonesCenter for Clinical and Translational Science, College of Nursing, The Ohio State University, Columbus, OH, USA.ORCID 0000-0002-0669-7860
Mark B MarchantThe University of Alabama at Birmingham, Birmingham, AL, USA.
Laura A RowleyNorth Carolina Biotechnology Center, Research Triangle Park, NC, USA.
Stephen A SonsteinMulti-Regional Clinical Trials Center of Brigham and Women's and Harvard, Cambridge MA, USA.
Karen M LipworthAssociation of Clinical Research Professionals, Alexandria, VA, USA.
Susan P LandisAssociation of Clinical Research Professionals, Alexandria, VA, USA.

Funding

Support for QA/QC for Prior Approval ProcessUL1TR002553 · NCATS · DUKE UNIVERSITY · PI LI, JENNIFER S, MCNAMARA, JAMES O. · 2018 to 2023
$58.5M
National Dissemination of I-Corps@NCATS: Accelerating Translation through CommercializationUL1TR003096 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GUTIERREZ, ORLANDO M, KIMBERLY, ROBERT P. · 2019 to 2023
$43.6M
The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve HealthUL1TR002733 · NCATS · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2018 to 2022
$28.9M
NCATS NIH HHS UL1 TR002553NCATS NIH HHS UL1 TR002733NCATS NIH HHS UL1 TR003096
6 · The paper itself

Abstract

The clinical and translational research enterprise is recognized by many as the "evidence generation system." While there have been several calls to revolutionize this enterprise to more effectively deliver the fruits of biomedical science to patients and society, significant issues across the clinical research workforce are pervasive. Perhaps the most visible sign is the widening gap between supply and demand for competent staff. Underpinning this, is a perfect storm of complex issues. Now reaching crisis point, this problem is far bigger than a staffing issue and ultimately jeopardizes the "engine" of drug and device development. With the current perilous state of the workforce, proposed enterprise fixes are likely to languish far out of reach, given that even "business as usual" is under threat. In fact, a glaring disconnect is evident between the visionary discourse on how to revolutionize the clinical research enterprise and the sober recognition that operationalization of any such vision rests on the shoulders of a workforce that's in dire straits. In this article, we provide a brief forensic analysis of the workforce problem and an initial indication of where solutions may lie.

Indexed as

Research DesignHumansWorkforceClinical researchclinical research coordinatorclinical research professionalclinical research workforcedrug developmentrecruitmentresearch nursingretentiontranslational researchworkforce development

Identifiers

PMID37264897
PMCPMC10504806

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.